Lexicon Pharmaceuticals gains FDA approval for heart failure drug
Lexicon Pharmaceuticals aiming to commercialise their recently approved heart failure drug in June, after receiving approval from the US FDA based on significant findings from two Phase III trials.
The US FDA has now approved an oral tablet for the treatment of heart failure from Lexicon Pharmaceuticals. Sotagliflozin, under the brand name INPEFA™, is taken once a day, to help reduce the risk of death from a cardiovascular event, hospitalisation due to heart failure, and urgent heart failure visits in adults diagnosed with heart failure, type 2 diabetes mellitus, chronic kidney disease, and other conditions leading to a greater risk of cardiovascular disease.
The approval covers a range of heart failure patients, including all of left ventricular ejection fraction (LVEF), and patients with or without diabetes.
“The approval of INPEFA along with the breadth of the label, is a major milestone in Lexicon’s path to fulfilling its mission of pioneering medicines that transform patients’ lives,” explained Lonnel Coats, Lexicon pharmaceutical’s Chief Executive Officer. “We expect this important innovation to be commercially available in the U.S. market by the end of June 2023.”
Sotagliflozin underwent the testing that eventually gained the approval in two randomised, double-blind, placebo-controlled Phase III clinical trials studying cardiovascular outcomes in patients who had heart failure or were at risk of heart failure, SOLOIST-WHF and SCORED. The trials included nearly 12,000 people.
In the SOLOIST-WHF trial, the drug was shown to significantly reduce the number of hospitalisations and urgent visits for heart failure, and cardiovascular death by 33% compared to the placebo group.
Sotagliflozin is part of the SGLT2 and SGLT1 class of inhibitors that are recommended for the treatment of heart failure by the American Heart Association (AHA), the American College of Cardiology (ACC), and the Heart Failure Society of America (HFSA) in their joint 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Experts from the associations decree that SGLT2 inhibitors in particular should be used in all patients with heart failure with preserved ejection fraction who are determined as stable during hospitalisation.
“Based on outcomes observed in the SOLOIST-WHF study, initiating treatment with INPEFA prior to or upon hospital discharge has the potential to reduce the burden of readmissions on patients, caregivers, providers, and health systems,” stated Craig Granowitz, Lexicon’s Senior Vice President and Chief Medical Officer. “With today’s FDA approval, INPEFA is now a valuable option for physicians to consider when treating patients transitioning out of the hospital and working to break the cycle of repeated hospitalisations.”
With this approval, Lexicon Pharmaceuticals hope that their treatment will be available for use by June 2023, with a comparable market pricing package for heart failure medications.
Related News
-
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Women in Pharma: Marketing for the other half in healthcare
In our new monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. This instalment highlights not only the importance of ma... -
News CAR-T therapy for renal cell carcinoma gains fast track approval
Joining the strong number of cancer therapies being approved in 2023 is the CAR-T cell therapy from Invectys, the clinical-stage immuno-oncology company. -
News CPHI Podcast Series: The ripple effects of nearshoring in pharma
In the most recent instalment of the CPHI Podcast Series, Digital Editor Lucy Chard is joined by Sandra Sánchez y Oldenhage, President and CEO of PharmAdvice, to discuss nearshoring and reshoring in the pharmaceutical industry, and the subs... -
News Bringing the pharmaceutical supply chain closer to home
The pharmaceutical supply chain has encountered numerous disruptions in the last few years, impacting procurement, manufacturing, packaging, and distribution operations within the pharmaceutical industry. Read about the rise in calls for near/resh... -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed. -
News Humira biosimilars at discounted prices to meet market demand for accessible treatment
Several biosimilars to AbbVie’s monoclonal antibody therapeutic Humira were launched by various pharmaceutical giants this week in the US, with more expected to be released by the end of the year as the patent expires. -
News President Biden's executive order to increase access to contraception
In the USA, President Joe Biden will be signing an executive order to expand access to contraception.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance